Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis.
Microglia in health and disease.
GlaxoSmithKline Product Development Pipeline
Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.
Biogen Idec's TECFIDERA™ (dimethyl fumarate) approved in US as a first-line oral treatment for multiple sclerosis
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Brain reserve against physical disability progression over 5 years in multiple sclerosis.
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Extracellular Cues Influencing Oligodendrocyte Differentiation and (Re)myelination.
Therapeutic plasma exchange and pregnancy: A case report and guidelines for performing plasma exchange in a pregnant patient.
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Mechanism of action of mitoxantrone.
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
Masitinib in Patients with Primary Progressive Multiple Sclerosis (PPMS) or Relapse-Free Secondary Multiple Sclerosis (SPMS)
“Human Medicines” page
B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages.
High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies.
[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients
Relationship between disease-modifying therapy and depression in multiple sclerosis.
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.
Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.

Pages